Last updated on July 2019

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors


Brief description of study

This study is an open-label Phase 1/Phase 2 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors.

Detailed Study Description

This study is an open-label Phase 1 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors.

Single Agent INCB001158:

Patients with advanced/metastatic solid tumors will be enrolled into escalating monotherapy dose cohorts to determine the Recommended Phase 2 Dose (RP2D) of INCB001158. Additional patients with NSCLC, Colorectal Cancer (CRC), and other tumors including SCCHN, RCC, Gastric, Bladder and Melanoma will be enrolled at the single agent RP2D.

Combination Treatment:

Patients with advanced/metastatic NSCLC, Melanoma, Urothelial, Microsatellite Instability (MSI)/ Microsatellite Stable (MSS) CRC, Gastric, SCCHN and Mesothelioma will be enrolled into separate cohorts of combination therapy (INCB001158 and Pembrolizumab) to determine the RP2D.

In the dose expansion phase, additional patients with NSCLC, Melanoma, Urothelial, MSI/MSS CRC, Gastric, SCCHN and Mesothelioma will be treated with the combination of INCB001158 and Pembrolizumab at the RP2D.

All patients will be assessed for safety, pharmacokinetics, biomarkers and tumor response.

Clinical Study Identifier: NCT02903914

Find a site near you

Start Over

University of Arizona

Tucson, AZ United States
  Connect »

Georgetown

Washington, WA United States
  Connect »

Johns Hopkins

Baltimore, MD United States
  Connect »

BIDMC

Boston, MA United States
  Connect »

DFCI

Boston, MA United States
  Connect »

Henry Ford

Detroit, MI United States
  Connect »

Vanderbilt

Nashville, TN United States
  Connect »

MD Anderson

Houston, TX United States
  Connect »

START

San Antonio, TX United States
  Connect »

NKI

Amsterdam, Netherlands
  Connect »

Radboudumc

Nijmegen, Netherlands
  Connect »